Novo Nordisk’s stock rallied after drugmaker reveals deal with OpenAI
Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce.
By · April 14, 2026 · 1 min read
This article was originally published by
MarketWatch
and is republished here under license.
Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce.
Leave a Reply